Blood borne pathogens or infected cells can be imaged with the AccuCyte system. For example, this capability is helping to make strides in the latest research being performed on Lyme disease.

The current standard-of-care tests measure the immune response for diagnosis. Because of this, they often fail to detect the agent responsible for Lyme and may come back negative early in the infection. This can delay treatment and proper diagnosis.

RareCyte's AccuCyte - CyteFinder system can detect Borrelia burgdorferi, the bacteria agent responsible for Lyme disease, even before the development of the immune response.

The work does not stop there. After treatment, the technology could potentially measure organisms in the bloodstream to see if the course of action was indeed truly effective.